All In Biotech

Drug Trial Radar · NCT07636785

A Phase 1 and 2 Study of VMD-102 in Hepatocellular Carcinoma and Other Solid Tumors

A Phase 1 and 2 First-in-human, Open-label, Multicenter Study to Assess the Safety, Tolerability and Preliminary Efficacy of VMD-102 in Participants With Hepatocellular Carcinoma and Other Advanced Solid Tumors

Last checked: Nov 19, 2026Latest source record: Nov 3, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

111

Planned (sponsor's estimate)

Start

Jul 16, 2026

Primary completion

May 2031

Study completion Dec 2031

Sponsor

Lead sponsor
VM Discovery, Inc.Industry
Sponsor type
Industry
First posted
Jun 9, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1 / Phase 2
Allocation
Not applicable (single group)
Model
Sequential
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 75 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This study is to evaluate the safety and tolerability to determine (i) the recommended Phase 2 dose (RP2D) of VMD-102 (Phase 1), and (ii) preliminary anti-tumor efficacy (Phase 2), in participants with advanced HCC, metastatic uveal melanoma (MUM), renal cell carcinoma (RCC), non-small cell lung cancer (NSCLC), and colorectal cancer (CRC). The pharmacokinetics (PK), preliminary anti-tumor activity, and potential biomarkers of VMD-102 will also be assessed. VMD-102 will be the first selective PKC epsilon (PKCε or PKCe) kinase inhibitor to enter human clinical testing. Preclinical VMD-102 anti-tumor activities in mouse liver/HCC tumor models and preclinical toxicology and pharmacology studies support this study.

Conditions

  • Hepatocellular Carcinoma (HCC)
  • Metastatic Uveal Melanoma
  • Renal Cell Carcinoma (RCC)
  • Nonsmall Cell Lung Cancer
  • Colorectal Cancer (CRC)

Interventions

  • VMD-102Drug

    A small organic molecule oral drug in the tablet form

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Number and severity of treatment-emergent adverse events (TEAE) (Phase 1)Time frame: First cycle (21 days per cycle)
  2. To determine the recommended Phase 2 dose (RP2D) for VMD-102 (Phase 1)Time frame: First cycle (21 days per cycle)
  3. Progression-Free Survival (PFS) (Phase 2)Time frame: Up to 18 months

Locations

2 sites in 1 country. Site status is shown where the registry gives one.

  • HonorHealth Research Institute (#600)

    Scottsdale, Arizona · Recruiting

  • The Angeles Clinic and Research Institute (#601)

    Los Angeles, California · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.